Mereo BioPharma Group plc (MREO) Form 10-Q — Aug 11, 2026
Mereo BioPharma's Q2 2026 net loss narrowed to $7.0 million from $14.6 million a year earlier on steep R&D and G&A cost reductions, with cash and equivalents of $30.1 million expected to fund operations into late 2027. The company disclosed a same-day Option and License Agreement with Sentynl Therapeutics for U.S. commercial and global manufacturing rights to alvelestat, under which Mereo is eligible to receive $40 million in upfront and R&D payments, up to $435 million in potential milestones, and double-digit tiered royalties on U.S. sales.
Key figures
- Revenue
- 0
- Total Debt
- 0
- Total Assets
- 34714000
- Cash Position
- 30118000
- Shares Outstanding
- 798454864
- Cash runway
- into late 2027
- Q2 net loss
- -7005000
- Q2 ga expense
- 5222000
- Q2 rnd expense
- 1808000
- Accumulated deficit
- 514543000
- Shareholders equity
- 28652000
- Sentynl potential milestones
- 435000000
- Sentynl upfront and rd payments
- 40000000
- Total historical financings gross
- 259000000
- Astrazeneca potential milestone payments
- 114300000
- Ultragenyx manufacturing slot cancellation costs
- 2300000
Price after filing
Close on the filing date to close N calendar days later (from $0.30). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.